FDA-approved GLP-1 receptor agonists (GLP-1 RAs), including liraglutide, lixisenatide, exenatide, dulaglutide, and semaglutide, are widely prescribed in the United States for the treatment of type 2 diabetes mellitus (T2DM) and complications [2,3]. This evidence concerns the gene GLP1R and diabetes mellitus.